Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia.
Standard
Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia. / Matza, Louis S; Phillips, Glenn A; Revicki, Dennis A; Ascher-Svanum, Haya; Malley, Karen G; Palsgrove, Andrew C; Faries, Douglas E; Stauffer, Virginia; Kinon, Bruce J; George Awad, A; Keefe, Richard S E; Naber, Dieter.
In: PSYCHIAT RES, Vol. 200, No. 2-3, 2-3, 2012, p. 835-842.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia.
AU - Matza, Louis S
AU - Phillips, Glenn A
AU - Revicki, Dennis A
AU - Ascher-Svanum, Haya
AU - Malley, Karen G
AU - Palsgrove, Andrew C
AU - Faries, Douglas E
AU - Stauffer, Virginia
AU - Kinon, Bruce J
AU - George Awad, A
AU - Keefe, Richard S E
AU - Naber, Dieter
PY - 2012
Y1 - 2012
N2 - The Reasons for Antipsychotic Discontinuation Questionnaire (RAD-Q) was designed to assess clinicians' perceptions of reasons for antipsychotic discontinuation or continuation. The current study examined psychometric properties of this instrument and patterns of antipsychotic discontinuation. The sample of 121 patients (81 discontinuation, 40 continuation) with schizophrenia or schizoaffective disorder was 66.9% male, with a mean age of 41.6 years. Treating clinicians reported a mean of 4.1 reasons for discontinuation and 7.5 reasons for continuation. RAD-Q domain scores were derived to quantify the impact of three factors on the decision to discontinue or continue: treatment benefits, adverse events, and distal reasons other than direct effects of the medication. Analysis of inter-rater reliability indicated an acceptable degree of agreement between clinicians (weighted Kappa for discontinuation scores=0.70-0.78). Correlations with symptom measures (Clinical Global Impression-Schizophrenia Scale (CGI-SCH), Positive and Negative Syndrome Scale (PANSS)) supported convergent validity of the benefits domain score (r=0.28-0.47; all p
AB - The Reasons for Antipsychotic Discontinuation Questionnaire (RAD-Q) was designed to assess clinicians' perceptions of reasons for antipsychotic discontinuation or continuation. The current study examined psychometric properties of this instrument and patterns of antipsychotic discontinuation. The sample of 121 patients (81 discontinuation, 40 continuation) with schizophrenia or schizoaffective disorder was 66.9% male, with a mean age of 41.6 years. Treating clinicians reported a mean of 4.1 reasons for discontinuation and 7.5 reasons for continuation. RAD-Q domain scores were derived to quantify the impact of three factors on the decision to discontinue or continue: treatment benefits, adverse events, and distal reasons other than direct effects of the medication. Analysis of inter-rater reliability indicated an acceptable degree of agreement between clinicians (weighted Kappa for discontinuation scores=0.70-0.78). Correlations with symptom measures (Clinical Global Impression-Schizophrenia Scale (CGI-SCH), Positive and Negative Syndrome Scale (PANSS)) supported convergent validity of the benefits domain score (r=0.28-0.47; all p
KW - Adult
KW - Humans
KW - Male
KW - Female
KW - Middle Aged
KW - Quality of Life
KW - Questionnaires
KW - Treatment Outcome
KW - Reproducibility of Results
KW - Antipsychotic Agents/therapeutic use
KW - Patient Satisfaction
KW - Schizophrenia/drug therapy
KW - Health Care Surveys
KW - Withholding Treatment/statistics & numerical data
KW - Adult
KW - Humans
KW - Male
KW - Female
KW - Middle Aged
KW - Quality of Life
KW - Questionnaires
KW - Treatment Outcome
KW - Reproducibility of Results
KW - Antipsychotic Agents/therapeutic use
KW - Patient Satisfaction
KW - Schizophrenia/drug therapy
KW - Health Care Surveys
KW - Withholding Treatment/statistics & numerical data
M3 - SCORING: Journal article
VL - 200
SP - 835
EP - 842
JO - PSYCHIAT RES
JF - PSYCHIAT RES
SN - 0165-1781
IS - 2-3
M1 - 2-3
ER -